Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;62(3):1369-1379.
doi: 10.3233/JAD-170662.

Metals and Alzheimer's Disease: How Far Have We Come in the Clinic?

Affiliations
Review

Metals and Alzheimer's Disease: How Far Have We Come in the Clinic?

Paul A Adlard et al. J Alzheimers Dis. 2018.

Abstract

It is estimated that by the year 2050 there will be more than 1.5 billion people globally over the age of 65 years. Aging is associated with changes to a number of different cellular processes which are driven by a variety of factors that contribute to the characteristic decline in function that is seen across multiple physiological domains/tissues in the elderly (including the brain). Importantly, aging is also the primary risk factor for the development of neurodegenerative disorders such as Alzheimer's disease. As such, there is an urgent need to provide a greater understanding of both the pathogenesis and treatment of these devastating neurodegenerative disorders. One of the key cellular processes that becomes dysregulated with age and participates both directly and indirectly in age-related dysfunction, is metal homeostasis and the neurochemistry of metalloproteins, the basic science of which has been extensively reviewed in the past. In this review, we will focus on the human clinical intervention trials that have been conducted over approximately the last four decades that have attempted to establish the efficacy of targeting metal ions in the treatment of AD.

Keywords: Alzheimer’s disease; clinical trials; copper; iron; metals; therapeutic; zinc.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Chemical structure of two iron chelators, deferiprone and deferoxamine (also known as desferrioxamine), highlighting the large structural differences in many of these compounds that chelate or modulate metals.

References

    1. Adlard PA, Bush AI (2006) Metals and Alzheimer’s disease. J Alzheimers Dis 10, 145–163. - PubMed
    1. Adlard PA, Bush AI (2012) Metal chaperones: A holistic approach to the treatment of Alzheimer’s disease. Front Psychiatry 3, 15. - PMC - PubMed
    1. Ayton S, Lei P, Bush AI (2013) Metallostasis in Alzheimer’s disease. Free Radic Biol Med 62, 76–89. - PubMed
    1. Ayton S, Lei P, Bush AI (2015) Biometals and their therapeutic implications in Alzheimer’s disease. Neurotherapeutics 12, 109–120. - PMC - PubMed
    1. Cicero CE, Mostile G, Vasta R, Rapisarda V, Signorelli SS, Ferrante M, Zappia M, Nicoletti A (2017) Metals and neurodegenerative diseases. A systematic review. Environ Res 159, 82–94. - PubMed

Publication types